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Omega-3 intake in people with epilepsy 
under regular hemodialysis program: here to stay
Suplementação de ômega 3 em pessoas com epilepsia 
submetidas a um programa regular de hemidiálise: veio para ficar
Carla Alessandra Scorza1, Ricardo Mario Arida2, Roberta Monterazzo Cysneiros3, Esper Abrão Cavalheiro1, 
Fulvio Alexandre Scorza1
The development of new treatments and effective 
strategies to prevent or reverse chronic human diseases 
must be the main goal of national health systems. This is 
easily established when the organization effectively trans-
lates findings in biomedical research into clinical prac-
tice and uses them on decision-makings in health policies. 
Translational medicine is the basis of this progress. This is 
a continued process that involves the direct application of 
discoveries from the bench to the development of studies 
in humans. It places together all results from these stud-
ies and applies them to clinical practice, in an attempt to 
improve health conditions and quality of life of the popu-
lation. It may also facilitate the adoption of best medical 
practices by the community.
In practice, this interdisciplinary approach works well in 
several fields1, however it is still unusual among nephrologists 
and neurologists. In Nephrology, it is generally accepted that 
chronic renal failure is a worldwide public health problem. 
People with this condition undergo dialysis treatment, may 
require kidney transplant and have an increased risk of car-
diovascular disease and hence sudden death2. In Neurology, 
the story is quite similar. Epilepsy is one of the most prevalent 
neurological diseases worldwide and mortality rates are con-
siderably higher in those that bear it3-6. 
Sudden unexpected death in epilepsy (SUDEP) is the 
main cause of death in people with chronic epilepsy3-6, ac-
counting for 17.0% of them. It has an incidence among epilep-
tic adults between 1:500 and 1:1,000 patient-years7. A single 
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AbstrAct
Among the many risk factors suggested for sudden unexpected death in epilepsy (SUDEP), higher frequency of seizures is a very consistent 
issue. Furthermore, it has been established that hemodialysis-associated seizure is a complication of the dialysis procedure. Thus, since a 
possible relation between cardiovascular abnormalities and SUDEP among patients with chronic renal insufficiency in regular hemodialysis 
program should not be neglected, we propose in this paper that omega-3 fatty acids offer opportunities for prevention of sudden cardiac 
death or improved treatment in people with epilepsy under the regular hemodialysis program.
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resumO
Dentre os fatores de risco sugeridos para a morte súbita inesperada em epilepsia (SUDEP), maior frequência de crises epilépticas é uma ques-
tão muito consistente. Além disso, tem sido estabelecido que as crises epilépticas associadas à hemodiálise são uma complicação do proce-
dimento dialítico. Desse modo, como a existência de uma possível associação entre as alterações cardiovasculares e a SUDEP entre indivíduos 
com insuficiência renal crônica em tratamento dialítico não deve ser negligenciada, foi proposto neste artigo que o ômega 3 pode atuar na 
prevenção da morte súbita cardíaca ou melhorar o tratamento de pessoas com epilepsia inseridas em um programa regular de hemodiálise.
Palavras-Chave: epilepsia, morte súbita, ômega-3, hemodiálise.
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mechanism is not established for SUDEP, but evidences sug-
gest that the major domain is cardiovascular dysregulation 
during and after seizures8-12. As these two chronic diseases 
are very common and have high rates of sudden death, we 
evaluated what would be the scenario if the same person had 
both conditions13. In order to do it, we investigated the rela-
tionship of seizure frequencies in people with end-stage renal 
disease (ESRD) under regular dialysis program14. Seven out 
of 189 ESRD cases had convulsive seizure during the dialytic 
program14, therefore it was evident that despite the belief that 
seizures were rare among ESRD individuals receiving dialysis, 
this was not the case. Indeed, this suggested that a clinical 
convergence of neurologists and nephrologists in the context 
would be helpful13-15. 
We also looked at a possible link between epilepsy, cardio-
vascular abnormalities, and SUDEP among ESRD cases under-
going regular hemodialysis13,16. It was found that abnormalities 
of cardiac rhythm and SUDEP are unusual events in this spe-
cific population (7 out of 209)13,16. This data has to be cautiously 
interpreted as the numbers examined are small, but our con-
clusion is that the flame of translational science among health 
professionals directly involved with these people must be per-
manently lit. For these new considerations, experimental, ep-
idemiological, and clinical studies should be carried out to 
establish the association between epilepsy, cardiovascular ab-
normalities, and sudden death in people on dialysis13,17.
Currently, the ultimate goal in neurology and nephrol-
ogy research in regards to cardiovascular changes that may 
lead to sudden death is to develop new methods to prevent it 
and to establish actions other than medical that may be effec-
tive. Therapy or supplementation with a ‘natural’ substance has 
shown interesting and promising benefits in this regard: the 
omega-3 fatty acids (omega-3 FAs). A number of experimental 
and clinical studies could be put forward to demonstrate the ef-
fectiveness of omega-3 FAs in epilepsy and dialysis fields.
In epilepsy, despite the need to perform clinical trials 
with higher doses and longer periods of omega-3 FAs to de-
finitively assess their anti-seizure effects, it is already well-es-
tablished that their supplementation reduces the convulsion 
frequency, promotes neuroprotection and positive neuro-
plastic changes in animal models and in some people with 
uncontrolled epilepsy18-23. Omega-3 FAs per se is able to im-
prove vascular and cardiac hemodynamics, triglycerides, au-
tonomic control, inflammation, thrombosis, arrhythmia and 
to reduce the risk of cardiac death, which may have implica-
tions for SUDEP prevention24,25. 
It has been postulated that omega-3 FAs supplemen-
tation in people with refractory epilepsy may not only re-
duce seizures but also their cardiac arrhythmias and hence 
SUDEP26. In these lines, a pilot, randomized, double-blind 
two-period crossover clinical trial of high-dose omega-3 FAs 
in 11 subjects with refractory seizures was carried out27. This 
was the first trial to demonstrate the beneficial effects of 
omega-3 FAs on cardiac risk factors and heart rate variability 
in people with epilepsy. It provided evidence that fish oil may 
reduce the risk of SUDEP in epilepsy27, which was also con-
firmed experimentally28-30.
In dialysis, omega-3 FAs have been clinically and experi-
mentally assessed due to their proven benefits in advanced 
chronic kidney disease (CKD), such as renoprotection in IgA 
nephropathy, cardioprotection via a variety of mechanisms 
including triglyceride levels and blood pressure reduction, 
maintenance of dialysis access patency, sparing of inflam-
mation-associated muscle loss, and reduced mortality17,31,32. 
In these lines, we fully agree with this and have recently con-
firmed it in a trial (Rui Alberto Gomes, PhD Thesis — unpub-
lished data). Briefly, we evaluated the omega-3 FAs effects 
on individuals under hemodialysis treatment with low qual-
ity of life and high mortality risk. Patients received daily sup-
plementation of 2 g omega-3 FAs in oral capsules, for three 
months, in a six-month period. Biochemical analysis was car-
ried out at three points, generating three groups of variables 
(before, during, and after omega-3 FAs supplementation). 
A reduction of inflammatory markers, with significant reduc-
tion of white blood cells in peripheral blood, in the glycemic, 
C-reactive protein and triglyceride levels, was seen. There was 
also a quality of life (QoL) score improvement on the SF-36 
instrument, especially in the physical health dimension (Rui 
Alberto Gomes, PhD Thesis — unpublished data). 
Given the importance of these results, the 2005 Kidney 
Disease Outcomes Quality Initiative Clinical Practice 
Guidelines specifically encourage further research on the ef-
fects of kidney failure and/or dialysis on omega-3 FAs metab-
olism and blood/tissue levels. It also calls the attention for 
clinical trials designed to evaluate the effects of omega-3 FAs 
supplementation on cardiovascular risk and outcomes17,31-33. 
It is important to note that sudden cardiac death is the most 
common cause of death in ESRD individuals under regular 
dialysis program usually caused by ventricular arrhythmias, 
such as ventricular tachycardia and fibrillation34. Therefore, 
omega-3 FAs supplementation can be of value in a preven-
tive strategy for cardiovascular abnormalities in individuals 
undergoing dialysis. This is due to its antiarrhythmic proper-
ties as well to its well-established ability to reduce the risk of 
cardiac death35.
The scientific field exploring omega-3 FAs is innovative, 
evolving, and promising. It needs, however, to be remem-
bered that humans cannot synthesize omega-3 FAs. Thus, 
it must be obtained from the diet36. The only aliments that 
provide large amounts of omega-3 with low levels of con-
taminants (i.e., methylmercury) are oily sea fish as ancho-
vies, herring, mackerel, salmon, sardines, and trouts37,38. 
Guidelines have converged on consistent recommendations 
for the general population to consume at least 250 mg/day 
of long-chain omega-3 FAs or at least two weekly servings of 
oily fish35. On that basis, fish is one of the most important 
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foodstuffs we can choose for cardiovascular and brain 
health. For individuals who do not tolerate fish or want a 
diet with no contaminants but at the same time are keen to 
enjoy the benefits of omega-3 FAs, options include fish oil 
supplements or the intake of some food, such as walnuts or 
oils ( flax, canola, and soybean)39,40.
While we are unable to prevent ESRD and epilepsy or to 
reverse the clinical scenario when they are installed, the use 
of omega-3 FAs could be an option to prevent cardiovascular 
abnormalities and hence sudden cardiac death in these pa-
tients. There is still the need to confirm the utility, and to es-
tablish intake recommendations and optimal dosing of ome-
ga-3 FAs32, however it is more than time to institute a task 
force to assess the state of knowledge (clinical management, 
research directions, and educational, social, and cultural ef-
forts) in order to put into practice these strategies.
Finally, these creative efforts about omega-3 FAs offer op-
portunities for preventing sudden cardiac death or improved 
treatment in people with epilepsy under regular hemodialy-
sis program. With this proposal, we should not forget the fa-
mous words of philosopher Socrates: “We do not live to eat 
but eat to live”.
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